Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest

Tomoko Hyoda, Takayuki Tsujioka, Takako Nakahara, Shin ichiro Suemori, Shuichiro Okamoto, Mikio Kataoka, Kaoru Tohyama

研究成果: ジャーナルへの寄稿記事

12 引用 (Scopus)

抄録

A multi-kinase inhibitor, rigosertib (ON 01910.Na) has recently been highlighted as a novel type of anti-cancer agent for the treatment of the myelodysplastic syndromes (MDS), but its action mechanisms remain to be clarified. We investigated the in vitro effects of rigosertib on an MDS-derived cell line MDS-L and a myeloid leukemia cell line HL-60. Rigosertib suppressed the proliferation of both HL-60 and MDS-L cells and induced apoptosis by inhibition of the PI3 kinase/Akt pathway. As the effects on cell cycle, rigosertib treatment promoted the phosphorylation of histone H2AX and led to the DNA damage-induced G2/M arrest. In addition, an immunofluorescence staining study demonstrated the abnormal localization of aurora A kinase, suggesting that rigosertib causes perturbation of spindle assembly and deregulated mitotic patterns towards cell cycle arrest and apoptosis. We also found that rigosertib exerted growth inhibitory effects on two lymphoid cell lines, Jurkat and Ramos. We further examined the molecular pathways influenced by rigosertib from the gene expression profiling data of MDS-L cells and found a possible involvement of rigosertib treatment in the upregulation of the genes related to microtubule kinetics and the downregulation of the mRNA degradation system. The gene set enrichment analysis showed the suppression of "nonsense-mediated mRNA decay (NMD)" as the most significantly affected gene set. These data provide a new aspect and a potential utility of rigosertib for the treatment of refractory hematopoietic malignancies.

元の言語英語
ページ(範囲)287-293
ページ数7
ジャーナルCancer Science
106
発行部数3
DOI
出版物ステータス出版済み - 3 1 2015
外部発表Yes

Fingerprint

Myelodysplastic Syndromes
DNA Damage
Cell Death
Cell Line
Aurora Kinase A
Nonsense Mediated mRNA Decay
ON 01910
Apoptosis
Genes
Myeloid Leukemia
RNA Stability
Gene Expression Profiling
Hematologic Neoplasms
Myeloid Cells
Therapeutics
Cell Cycle Checkpoints
Phosphatidylinositol 3-Kinases
Microtubules
Histones
Fluorescent Antibody Technique

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Hyoda, T., Tsujioka, T., Nakahara, T., Suemori, S. I., Okamoto, S., Kataoka, M., & Tohyama, K. (2015). Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest. Cancer Science, 106(3), 287-293. https://doi.org/10.1111/cas.12605

Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest. / Hyoda, Tomoko; Tsujioka, Takayuki; Nakahara, Takako; Suemori, Shin ichiro; Okamoto, Shuichiro; Kataoka, Mikio; Tohyama, Kaoru.

:: Cancer Science, 巻 106, 番号 3, 01.03.2015, p. 287-293.

研究成果: ジャーナルへの寄稿記事

Hyoda, T, Tsujioka, T, Nakahara, T, Suemori, SI, Okamoto, S, Kataoka, M & Tohyama, K 2015, 'Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest', Cancer Science, 巻. 106, 番号 3, pp. 287-293. https://doi.org/10.1111/cas.12605
Hyoda, Tomoko ; Tsujioka, Takayuki ; Nakahara, Takako ; Suemori, Shin ichiro ; Okamoto, Shuichiro ; Kataoka, Mikio ; Tohyama, Kaoru. / Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest. :: Cancer Science. 2015 ; 巻 106, 番号 3. pp. 287-293.
@article{b5ef0da968c746468c6fe954dc5dfb89,
title = "Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest",
abstract = "A multi-kinase inhibitor, rigosertib (ON 01910.Na) has recently been highlighted as a novel type of anti-cancer agent for the treatment of the myelodysplastic syndromes (MDS), but its action mechanisms remain to be clarified. We investigated the in vitro effects of rigosertib on an MDS-derived cell line MDS-L and a myeloid leukemia cell line HL-60. Rigosertib suppressed the proliferation of both HL-60 and MDS-L cells and induced apoptosis by inhibition of the PI3 kinase/Akt pathway. As the effects on cell cycle, rigosertib treatment promoted the phosphorylation of histone H2AX and led to the DNA damage-induced G2/M arrest. In addition, an immunofluorescence staining study demonstrated the abnormal localization of aurora A kinase, suggesting that rigosertib causes perturbation of spindle assembly and deregulated mitotic patterns towards cell cycle arrest and apoptosis. We also found that rigosertib exerted growth inhibitory effects on two lymphoid cell lines, Jurkat and Ramos. We further examined the molecular pathways influenced by rigosertib from the gene expression profiling data of MDS-L cells and found a possible involvement of rigosertib treatment in the upregulation of the genes related to microtubule kinetics and the downregulation of the mRNA degradation system. The gene set enrichment analysis showed the suppression of {"}nonsense-mediated mRNA decay (NMD){"} as the most significantly affected gene set. These data provide a new aspect and a potential utility of rigosertib for the treatment of refractory hematopoietic malignancies.",
author = "Tomoko Hyoda and Takayuki Tsujioka and Takako Nakahara and Suemori, {Shin ichiro} and Shuichiro Okamoto and Mikio Kataoka and Kaoru Tohyama",
year = "2015",
month = "3",
day = "1",
doi = "10.1111/cas.12605",
language = "English",
volume = "106",
pages = "287--293",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest

AU - Hyoda, Tomoko

AU - Tsujioka, Takayuki

AU - Nakahara, Takako

AU - Suemori, Shin ichiro

AU - Okamoto, Shuichiro

AU - Kataoka, Mikio

AU - Tohyama, Kaoru

PY - 2015/3/1

Y1 - 2015/3/1

N2 - A multi-kinase inhibitor, rigosertib (ON 01910.Na) has recently been highlighted as a novel type of anti-cancer agent for the treatment of the myelodysplastic syndromes (MDS), but its action mechanisms remain to be clarified. We investigated the in vitro effects of rigosertib on an MDS-derived cell line MDS-L and a myeloid leukemia cell line HL-60. Rigosertib suppressed the proliferation of both HL-60 and MDS-L cells and induced apoptosis by inhibition of the PI3 kinase/Akt pathway. As the effects on cell cycle, rigosertib treatment promoted the phosphorylation of histone H2AX and led to the DNA damage-induced G2/M arrest. In addition, an immunofluorescence staining study demonstrated the abnormal localization of aurora A kinase, suggesting that rigosertib causes perturbation of spindle assembly and deregulated mitotic patterns towards cell cycle arrest and apoptosis. We also found that rigosertib exerted growth inhibitory effects on two lymphoid cell lines, Jurkat and Ramos. We further examined the molecular pathways influenced by rigosertib from the gene expression profiling data of MDS-L cells and found a possible involvement of rigosertib treatment in the upregulation of the genes related to microtubule kinetics and the downregulation of the mRNA degradation system. The gene set enrichment analysis showed the suppression of "nonsense-mediated mRNA decay (NMD)" as the most significantly affected gene set. These data provide a new aspect and a potential utility of rigosertib for the treatment of refractory hematopoietic malignancies.

AB - A multi-kinase inhibitor, rigosertib (ON 01910.Na) has recently been highlighted as a novel type of anti-cancer agent for the treatment of the myelodysplastic syndromes (MDS), but its action mechanisms remain to be clarified. We investigated the in vitro effects of rigosertib on an MDS-derived cell line MDS-L and a myeloid leukemia cell line HL-60. Rigosertib suppressed the proliferation of both HL-60 and MDS-L cells and induced apoptosis by inhibition of the PI3 kinase/Akt pathway. As the effects on cell cycle, rigosertib treatment promoted the phosphorylation of histone H2AX and led to the DNA damage-induced G2/M arrest. In addition, an immunofluorescence staining study demonstrated the abnormal localization of aurora A kinase, suggesting that rigosertib causes perturbation of spindle assembly and deregulated mitotic patterns towards cell cycle arrest and apoptosis. We also found that rigosertib exerted growth inhibitory effects on two lymphoid cell lines, Jurkat and Ramos. We further examined the molecular pathways influenced by rigosertib from the gene expression profiling data of MDS-L cells and found a possible involvement of rigosertib treatment in the upregulation of the genes related to microtubule kinetics and the downregulation of the mRNA degradation system. The gene set enrichment analysis showed the suppression of "nonsense-mediated mRNA decay (NMD)" as the most significantly affected gene set. These data provide a new aspect and a potential utility of rigosertib for the treatment of refractory hematopoietic malignancies.

UR - http://www.scopus.com/inward/record.url?scp=84925797798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925797798&partnerID=8YFLogxK

U2 - 10.1111/cas.12605

DO - 10.1111/cas.12605

M3 - Article

C2 - 25580850

AN - SCOPUS:84925797798

VL - 106

SP - 287

EP - 293

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 3

ER -